Vericel (VCEL) Competitors $52.00 -2.31 (-4.25%) Closing price 04:00 PM EasternExtended Trading$52.00 +0.01 (+0.01%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VCEL vs. PCVX, SRPT, QGEN, ASND, ROIV, RVMD, LEGN, BBIO, AXSM, and BPMCShould you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Vericel vs. Vaxcyte Sarepta Therapeutics Qiagen Ascendis Pharma A/S Roivant Sciences Revolution Medicines Legend Biotech BridgeBio Pharma Axsome Therapeutics Blueprint Medicines Vaxcyte (NASDAQ:PCVX) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk. Which has more risk & volatility, PCVX or VCEL? Vaxcyte has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Is PCVX or VCEL more profitable? Vericel has a net margin of 1.56% compared to Vaxcyte's net margin of 0.00%. Vericel's return on equity of 1.48% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -23.53% -22.20% Vericel 1.56%1.48%0.96% Do analysts recommend PCVX or VCEL? Vaxcyte currently has a consensus target price of $127.71, suggesting a potential upside of 60.16%. Vericel has a consensus target price of $63.14, suggesting a potential upside of 21.43%. Given Vaxcyte's higher possible upside, equities analysts clearly believe Vaxcyte is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, PCVX or VCEL? Vericel has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$402.27M-$4.60-17.33Vericel$197.52M12.99-$3.18M$0.06866.81 Do institutionals and insiders hold more shares of PCVX or VCEL? 96.8% of Vaxcyte shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 5.2% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer PCVX or VCEL? In the previous week, Vaxcyte and Vaxcyte both had 7 articles in the media. Vericel's average media sentiment score of 1.40 beat Vaxcyte's score of 1.08 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in PCVX or VCEL? Vericel received 306 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 75.41% of users gave Vaxcyte an outperform vote while only 61.86% of users gave Vericel an outperform vote. CompanyUnderperformOutperformVaxcyteOutperform Votes4675.41% Underperform Votes1524.59% VericelOutperform Votes35261.86% Underperform Votes21738.14% SummaryVericel beats Vaxcyte on 11 of the 15 factors compared between the two stocks. Get Vericel News Delivered to You Automatically Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCEL vs. The Competition Export to ExcelMetricVericelBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.57B$3.12B$5.80B$8.94BDividend YieldN/A1.57%4.78%3.85%P/E Ratio867.2430.1226.4118.84Price / Sales13.00320.52450.1476.68Price / Cash3,278.86183.5344.0437.47Price / Book11.003.567.634.64Net Income-$3.18M-$71.72M$3.18B$245.69M7 Day Performance-8.87%-2.45%-1.82%-2.59%1 Month Performance-12.65%0.36%0.22%-2.30%1 Year Performance8.09%-11.49%17.25%13.71% Vericel Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCELVericel2.9323 of 5 stars$52.00-4.3%$63.14+21.4%+9.7%$2.57B$197.52M866.81300Positive NewsPCVXVaxcyte2.5867 of 5 stars$84.00+0.2%$127.71+52.0%+11.3%$10.47BN/A-18.26160Insider TradePositive NewsSRPTSarepta Therapeutics4.4962 of 5 stars$107.95-1.4%$176.77+63.8%-20.4%$10.31B$1.24B86.361,314Upcoming EarningsQGENQiagen4.4279 of 5 stars$39.85-0.5%$48.78+22.4%-7.3%$8.84B$1.98B110.975,967Analyst DowngradeASNDAscendis Pharma A/S3.1758 of 5 stars$144.08+1.1%$193.43+34.3%-1.4%$8.74B$288.08M-17.83640Analyst ForecastROIVRoivant Sciences2.7251 of 5 stars$10.56+1.1%$18.08+71.2%-7.1%$7.69B$122.59M1.87860Insider TradeRVMDRevolution Medicines4.5108 of 5 stars$40.67-1.6%$66.25+62.9%+44.9%$6.84B$11.58M-11.33250LEGNLegend Biotech2.5939 of 5 stars$36.42+0.1%$79.50+118.3%-35.2%$6.65B$285.14M-38.341,800Positive NewsBBIOBridgeBio Pharma4.7193 of 5 stars$34.90+10.6%$49.08+40.6%+2.4%$6.60B$9.30M-14.48400Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap UpAXSMAxsome Therapeutics4.5264 of 5 stars$131.15-0.4%$147.13+12.2%+59.2%$6.36B$270.60M-20.08380Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBPMCBlueprint Medicines2.9925 of 5 stars$93.94-1.3%$123.83+31.8%+3.4%$5.97B$249.38M-44.52640Earnings Report Related Companies and Tools Related Companies PCVX Competitors SRPT Competitors QGEN Competitors ASND Competitors ROIV Competitors RVMD Competitors LEGN Competitors BBIO Competitors AXSM Competitors BPMC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VCEL) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
